Company intelligence / Profile preview
Spero Therapeutics
Cambridge, Massachusetts, United Statessperotherapeutics.com ↗
- Ownership
- Public · SPRO
- Employees
- ~75
- Development stage
- Phase 3
01
Overview
Spero’s lead asset, tebipenem HBr, an oral carbapenem antibiotic for cUTI and AP, is in a global Phase 3 trial (“PIVOT-PO”) with enrollment expected to complete in the second half of 2025. If approved, it would be the first oral carbapenem for these indications. SPR720 completed enrollment in a Phase 2a proof-of-concept trial for NTM-PD; topline data are expected Q4 2024 but development has been suspended pending full data review due to disappointing results and safety concerns. The SPR206 program was discontinued after pipeline reprioritization in early 2025.
- Therapeutic areas
- Infectious Diseases
- Modalities
- Small molecules (oral antibiotics)
- Industry
- Biotech
02
Drug pipeline
6 assets5 more assets in the full pipeline.
03
Partnerships
GlaxoSmithKline (GSK) – exclusive license agreement to commercialize tebipenem HBr outside certain Asian territories; GSK provided $66 million upfront and milestone payments supporting ongoing developmentU.S. government agencies previously supported now-discontinued programs via funding from Department of Defense, NIH/NIAID/HHS
04
Financials
- Market cap
- $59.4M
- Total revenue
- $59.6M
- Enterprise value
- $10.7M
Beyond the preview
Go deeper on Spero Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Spero Therapeutics.